Q-omics provides the consensus-scored ANK1 profile across patient tissues and cancer cell-line models. ANK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANK1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANK1 protein abundance shows 24,428 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where ANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANK1 survival associations across molecular data types. ANK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (16) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANK1 RNA expression–survival associations across cancer types. High ANK1 expression shows unfavorable associations in MESO, UVM and LUSC, but favorable associations in CESC, ACC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANK1 RNA expression.
This table summarizes ANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANK1 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, UCEC, LUSC and STAD. The KIRC box plot shows higher ANK1 RNA expression in tumor versus normal tissue (log2 FC = +1.427, t-test p < 0.001).
This table shows molecular features associated with ANK1 in patient tissues and cancer cell lines. In patient samples, ANK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
